In this press release, all per share amounts are calculated on a fully diluted basis, and all results are presented on a U.S. GAAP basis. Some totals may not foot due to rounding.
Gen-Probe's clinical diagnostics sales in the third quarter of 2008 benefited from continued growth of the APTIMA Combo 2(R) assay, an amplified nucleic acid test (NAT) for simultaneously detecting Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC). Sales of this assay increased based on market share gains on both the Company's semi-automated instrument platform and on the high-throughput, fully automated TIGRIS(R) system. Revenue from the PACE(R) product line, the Company's non-amplified tests for the same microorganisms, declined in the third quarter compared to the prior year period, in line with Gen-Probe's expectations.
In blood screening, product sales in the third quarter of 2008
benefited from increased international and domestic sales of the
PROCLEIX(R) ULTRIO(R) assay, and from approximately $1.8 million of foreign
exchange benefit compared to the prior year. Chiron, a business unit of
Novartis Vaccines and Diagnostics, markets the Company's blood screening
Product sales were, in millions:
Three Months Ended Nine Months Ended
Sept. 30, Sept. 30,
2008 2007 Increase 2008 2007 Increase
Clinical diagnostics $55.5 $51.8* 7% $165.2 $149.5 11%
Blood screening $52.7 $45.6 16% $158.2 $129.0 23%
Total product sales $108.3 $97.4 11% $323.5 $278.5 16%
* As previously disclosed, clinical diagnostics sales in the third quarter
of 2007 included approximately $3 million of one-time, incremental
instrument sales. Excluding these sales from the prior year period,
|SOURCE Gen-Probe Incorporated|
Copyright©2008 PR Newswire.
All rights reserved